Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Intravesikales Gemcitabin für nicht-muskelinvasive Harnblasenkarzinome

Intravesical gemcitabine for non-muscle invasive bladder cancer

  • 195 Accesses

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Bohle A, Leyh H, Frei C et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo controlled phase III multicentre study. Eur Urol 56:495–503

  2. 2.

    Gardmark T, Carringer M, Beckman E et al (2005) Randomised phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder. Urology 66:527–530

  3. 3.

    Addeo R, Caraglia M, Belini S et al (2009) Randomised phase III trial on Gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543–558

  4. 4.

    Bendary L, Khalil S, Shahin A et al (2011) Intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study. Conference Proceedings American Urological Association 185 (4 Suppl 1):664–665

  5. 5.

    Porena M, Zingaro M, Lazzeri M et al (2010) Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in highrisk superficial bladder cancer: a randomised prospective study. Urol Int 84:23–27

  6. 6.

    Lorenzo GD, Perdona S, Damiano R et al (2010) Gemcitabine versus Bacille Calmette-Guerin after initial Bacille Calmette-Guerin failure in non-muscle invasive bladder cancer. Cancer 116:1893–1900

  7. 7.

    Brausi MA, Gontero P, Altieri V et al (2011) Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study. Urol Int 87(4):470–474

  8. 8.

    Cao M, Ma CK, Ma J et al (2011) Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer. Zhonghua Zhong Liu Za Zhi 33(5):385–387

  9. 9.

    Gontero P, Oderda M, Mehnert A et al (2013) The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II Trial. Urology 3:857–862

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. L.-M. Krabbe und S. Schmidt sind Mitglieder von UroEvidence. Es bestehen keine Interessenskonflikte. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Correspondence to Dr. L.-M. Krabbe or S. Schmidt , PhD, MPH.

Additional information

Die Zusammenfassung der Studie ist die Übersetzung des englischen Abstracts der Originalpublikation.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Krabbe, L., Schmidt, S. Intravesikales Gemcitabin für nicht-muskelinvasive Harnblasenkarzinome. Urologe 54, 402–405 (2015). https://doi.org/10.1007/s00120-015-3779-2

Download citation